INTRODUCTION: Little is known on continued response following completion of therapy in light chain (AL) amyloidosis. METHODS: We studied 373 AL amyloidosis patients who achieved complete response (CR) or very good partial response (VGPR) to first-line therapy. RESULTS: By end of therapy (EOT), 46% of patients achieved a CR and 54% a VGPR. With no further therapy, 17.5% of patients were upstaged from VGPR to CR (delayed CR), with a median of 9 months. Compared with CR and VGPR at EOT, patients with a delayed CR were characterized by higher proportion of t(11;14) and lower rate of trisomies. Autologous stem cell transplant was more frequent in the delayed CR group. Patients with a delayed CR were characterized by minimal residual disease negativity and organ response rates similar to patients with CR at EOT and higher than patients achieving VGPR at EOT. Patients with a delayed CR had a longer PFS/OS compared to patients with CR or VGPR by EOT (median PFS 149 vs 92 vs 52 months, P < .001; 10-year OS 87% vs 71% vs 56%, P < .001). CONCLUSIONS: This study characterizes delayed CR in AL amyloidosis, highlights its prognostic impact which is at least similar to those who achieved CR at EOT, and underlines another aspect of response monitoring.
INTRODUCTION: Little is known on continued response following completion of therapy in light chain (AL) amyloidosis. METHODS: We studied 373 AL amyloidosis patients who achieved complete response (CR) or very good partial response (VGPR) to first-line therapy. RESULTS: By end of therapy (EOT), 46% of patients achieved a CR and 54% a VGPR. With no further therapy, 17.5% of patients were upstaged from VGPR to CR (delayed CR), with a median of 9 months. Compared with CR and VGPR at EOT, patients with a delayed CR were characterized by higher proportion of t(11;14) and lower rate of trisomies. Autologous stem cell transplant was more frequent in the delayed CR group. Patients with a delayed CR were characterized by minimal residual disease negativity and organ response rates similar to patients with CR at EOT and higher than patients achieving VGPR at EOT. Patients with a delayed CR had a longer PFS/OS compared to patients with CR or VGPR by EOT (median PFS 149 vs 92 vs 52 months, P < .001; 10-year OS 87% vs 71% vs 56%, P < .001). CONCLUSIONS: This study characterizes delayed CR in AL amyloidosis, highlights its prognostic impact which is at least similar to those who achieved CR at EOT, and underlines another aspect of response monitoring.
Authors: Giampaolo Merlini; Angela Dispenzieri; Vaishali Sanchorawala; Stefan O Schönland; Giovanni Palladini; Philip N Hawkins; Morie A Gertz Journal: Nat Rev Dis Primers Date: 2018-10-25 Impact factor: 52.329
Authors: R L Comenzo; D Reece; G Palladini; D Seldin; V Sanchorawala; H Landau; R Falk; K Wells; A Solomon; A Wechalekar; J Zonder; A Dispenzieri; M Gertz; H Streicher; M Skinner; R A Kyle; G Merlini Journal: Leukemia Date: 2012-04-05 Impact factor: 11.528
Authors: Surbhi Sidana; Eli Muchtar; M Hasib Sidiqi; Dragan Jevremovic; Angela Dispenzieri; Wilson Gonsalves; Francis Buadi; Martha Q Lacy; Suzanne R Hayman; Taxiarchis Kourelis; Prashant Kapoor; Ronald S Go; Rahma Warsame; Nelson Leung; S Vincent Rajkumar; Robert A Kyle; Morie A Gertz; Shaji K Kumar Journal: Am J Hematol Date: 2020-02-14 Impact factor: 10.047
Authors: A Arteche-López; A Kreutzman; A Alegre; P Sanz Martín; B Aguado; M González-Pardo; M Espiño; L M Villar; D García Belmonte; R de la Cámara; C Muñoz-Calleja Journal: Bone Marrow Transplant Date: 2017-04-03 Impact factor: 5.483
Authors: John R Mills; Mindy C Kohlhagen; Surendra Dasari; Patrick M Vanderboom; Robert A Kyle; Jerry A Katzmann; Maria A V Willrich; David R Barnidge; Angela Dispenzieri; David L Murray Journal: Clin Chem Date: 2016-08-18 Impact factor: 8.327
Authors: Vaishali Sanchorawala; Shayna Sarosiek; Amanda Schulman; Meredith Mistark; Mary Ellen Migre; Ramon Cruz; J Mark Sloan; Dina Brauneis; Anthony C Shelton Journal: Blood Date: 2020-04-30 Impact factor: 22.113
Authors: E Muchtar; A Dispenzieri; S K Kumar; F K Buadi; M Q Lacy; S Zeldenrust; S R Hayman; N Leung; T V Kourelis; W Gonsalves; R Chakraborty; S Russell; D Dingli; J A Lust; Y Lin; P Kapoor; R Go; R A Kyle; S V Rajkumar; M A Gertz Journal: Leukemia Date: 2016-05-23 Impact factor: 11.528
Authors: M Hasib Sidiqi; Mohammed A Aljama; Dragan Jevremovic; Eli Muchtar; Francis K Buadi; Rahma Warsame; Martha Q Lacy; Angela Dispenzieri; David Dingli; Wilson I Gonsalves; Shaji Kumar; Prashant Kapoor; Taxiarchis Kourelis; Nelson Leung; William J Hogan; Morie A Gertz Journal: Biol Blood Marrow Transplant Date: 2018-06-30 Impact factor: 5.742
Authors: Eli Muchtar; Angela Dispenzieri; Nelson Leung; Martha Q Lacy; Francis K Buadi; David Dingli; Suzanne R Hayman; Prashant Kapoor; Yi Lisa Hwa; Amie Fonder; Miriam Hobbs; Wilson Gonsalves; Taxiarchis V Kourelis; Rahma Warsame; Stephen J Russell; John A Lust; Yi Lin; Ronald S Go; Steven R Zeldenrust; Robert A Kyle; S Vincent Rajkumar; Shaji K Kumar; Morie A Gertz Journal: Leukemia Date: 2018-09-26 Impact factor: 11.528